| Order from | Reserve Bank of India |
|---|
BSE filing, NSE: IBULLSLTD. Summary written from the filing by ALFA Finder's alert engine.
Indiabulls Ltd: key numbers
- Share price
- ₹31.88
- Market cap
- ₹7,435 Cr
- Revenue (annual)
- ₹833.4 Cr
- Net profit (annual)
- ₹273.9 Cr
- P/E (TTM)
- 17.7×Sector 43.1×
- Promoter holding
- 32.87%-0.04% QoQ
- FII holding
- 13.42%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Indiabulls Ltd
All →Indiabulls Other Announcement
Indiabulls Limited filed its shareholding pattern for the quarter ended September 30, 2026. This is a routine regulatory compliance filing.
Indiabulls Price Movement Clarification
Indiabulls Ltd replied to NSE's price-movement surveillance query, stating no undisclosed information exists. No material business event is communicated to the market.
Indiabulls Other Announcement
Employee Amiteshwar Choudhary sold shares worth Rs. 0.32 Crore via market sale. This is a routine PIT Regulation 7(2) disclosure.
- Value
- ₹0.32 Cr
Indiabulls Other Announcement
Indiabulls Limited has submitted the certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.
Indiabulls Promoter Buying (Off-Market)
Phanes Limited, a promoter group entity, was allotted 22,52,50,000 convertible warrants in Indiabulls Limited. The preferential allotment increases the promoter group's potential stake on a diluted basis.
- Promoter stake change
- -0.01%
Indiabulls Capital Structure Change
Indiabulls Ltd allotted 365.5 million warrants to promoter group entities Hermes Limited and Phanes Limited via a preferential offer, raising ₹177.27 Crore capital.
- Value
- ₹177.3 Cr
Other regulatory approval announcements
All →Shalby Regulatory Approval
Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.
Elantas Beck India Regulatory Approval
Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.
Kalyani Cast-Tech Regulatory Approval
Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.
Mukka Proteins Regulatory Approval
Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.
- Execution
- October 1, 2026 to December 31, 2027
Canara Bank Regulatory Approval
Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.
- Value
- ₹1,500 Cr
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.